Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion - Public policy

5246 - Reaching sustainable oncology care via the National Cancer Control Program (NCCP)

Date

29 Sep 2019

Session

Poster Discussion - Public policy

Presenters

Branko Zakotnik

Citation

Annals of Oncology (2019) 30 (suppl_5): v671-v682. 10.1093/annonc/mdz263

Authors

B. Zakotnik1, V. Zadnik2, T. Žagar2, M. Primic Žakelj2, U. Ivanuš2, T. Jerman2, J. Maučec Zakotnik3, D. Novak Mlakar3, T. Kofol Bric3, M. Kadivec2, K. Jarm2

Author affiliations

  • 1 Medical Oncology, Institute of Oncology Ljubljana, 1000 - Ljubljana/SI
  • 2 Cancer Registry, Institute of Oncology Ljubljana, 1000 - Ljubljana/SI
  • 3 Non Communicable Diseases, National Institute of Public Health, 1000 - Ljubljana/SI

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5246

Background

The NCCP is a program of activities for efficient action in the field of cancer control adopted by our Government and based on recommendations of WHO and European Partnership Action Against Cancer. It was initiated due to high cancer incidence and mortality in our country. We report achievements of our 3 organized, population-based screening programs (SP).

Methods

1. Cervical Cancer (CerC) SP, started 2003, conventional cytology, 3 years interval, age 20–64, participation 72%. 2. Colorectal Cancer (CRC) SP, started 2009, immunochemical fecal occult blood test, follow up colonoscopy if positive, age 50-74, 2 years interval, participation 62%. 3. Breast Cancer (BC) SP, started 2008 in central region, countrywide in 2018, mammography every 2 years, age 50-69, participation 73%. Outcome measures: 1. Incidence for CerC and CRC for all pts diagnosed in Slovenia from SP start. 2. Stage distribution, net survival and hazard ratio (HR) of death for screen vs not screen detected cancers diagnosed with CerC, CRC and BC from 2011-2015 for all invited patients to the SPs.

Results

CerC incidence was reduced from 2003 to 2017 by 62% (from 211 cases/year to 85), CRC from 2010 to 2015 by 21% (from 1729 cases/year to 1357). A significant (p < 0.0001) stage shift in screen detected vs not screen detected cancers was achieved. The stage shift percentages (screen detected/not screen detected) for the three SP are: for CerC stage I 81/41; stage II 16/30; stage III 3/19; stage IV 1/10, for CRC stage I 45/14; stage II 19/24; stage III 29/33; stage IV 8/30 and for BC stage I 66/40; stage II 26/35 stage III 8/18; stage IV 1/7. 5-year net survival for screen detected pts with CerC, CRC and BC was 92.1%, 88.4% and 100% and in not screen detected 63.7%, 57.1%, 85.3% respectively. The risk of death described by hazard ratio is in screened detected cancers 4-5 times lower: CerC HR 0.18 (0.11 – 0.28), CRC HR 0.26 (0.23-0.29) and BC HR 0.17 (0.10-0.31).

Conclusions

High quality SPs have a significant impact on incidence, stage and survival and are the basis of sustainable oncology care. They are even more essential in countries with limited human and financial resources. Pts with screen detected cancers are diagnosed in earlier stages and have lower probability to die from cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.